PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33906643-0	2021	Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.	glecaprevir	34-45	DNA damage inducible transcript 3	Homo sapiens	94-98
6792848-4	1981	Oe1 and Oe2 are equally effective, even with consideration of metabolic conversion of O31 into Oe2.	glecaprevir	86-89	EBF transcription factor 1	Homo sapiens	0-3
6792848-4	1981	Oe1 and Oe2 are equally effective, even with consideration of metabolic conversion of O31 into Oe2.	glecaprevir	86-89	EBF transcription factor 3	Homo sapiens	8-11
6792848-4	1981	Oe1 and Oe2 are equally effective, even with consideration of metabolic conversion of O31 into Oe2.	glecaprevir	86-89	EBF transcription factor 3	Homo sapiens	95-98
33906643-3	2021	CASE PRESENTATION: We report the first case of effective and safe treatment with on-demand 8-week glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in a patient with diffuse large B-cell lymphoma (DLBCL).	glecaprevir	98-109	DNA damage inducible transcript 3	Homo sapiens	158-162
31682879-15	2020	CONCLUSIONS: Eight-week glecaprevir/pibrentasvir was well tolerated and led to a similarly high SVR12 rate as the 12-week regimen in treatment-naive patients with chronic HCV GT1-6 infection and compensated cirrhosis.	glecaprevir	24-35	beta-1,4-galactosyltransferase 1	Homo sapiens	175-178
33645457-5	2021	Current study, based on docking and extensive set of MD simulations, finds the combination of Elbasvir, Glecaprevir and Ritonavir to be a viable candidate for further experimental drug testing/pharmacophore design for Mpro.Communicated by Ramaswamy H. Sarma.	glecaprevir	104-115	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	218-222
32441299-5	2020	Using well-defined computational methods, we identified Glecaprevir and Maraviroc (MVC) as the best inhibitors of SARS-CoV-2 Mpro.	glecaprevir	56-67	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	125-129
32441299-7	2020	Glecaprevir and MVC bind to the conserved residues of substrate-binding pocket of SARS-CoV-2 Mpro.	glecaprevir	0-11	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	93-97
33430709-0	2021	Exploring of paritaprevir and glecaprevir resistance due to A156T mutation of HCV NS3/4A protease: molecular dynamics simulation study.	glecaprevir	30-41	ns3/4a protease	None	82-97
33430709-3	2021	Paritaprevir and glecaprevir, the newly FDA-approved HCV drugs, exhibit distinct resistance profiles against the A156T mutation of HCV NS3/4A serine protease.	glecaprevir	17-28	ns3/4a serine protease	None	135-157
33430709-5	2021	QM/MM-GBSA-based binding free energy calculations revealed that the binding affinities of paritaprevir and glecaprevir towards A156T NS3/4A were significantly reduced by ~4 kcal/mol with respect to their WT complexes, which were in line with the experimental resistance folds.	glecaprevir	107-118	KRAS proto-oncogene, GTPase	Homo sapiens	133-136
33430709-6	2021	Moreover, the relatively weak intermolecular interactions with amino acids such as H57, R155, and T156 of NS3 protein, the steric effect and the destabilized protein binding surface, which is caused by the loss of salt bridge between R123 and D168, are the main contributions for the higher fold-loss in potency of glecaprevir due to A156T mutation.	glecaprevir	315-326	KRAS proto-oncogene, GTPase	Homo sapiens	106-109
33168456-9	2020	Similarly Indinavir showed the highest binding energy of -11.5 kcal/mol against the target protein RdRp and Dolutegravir, Elbasvir, Tipranavir, Taltegravir, Grazoprevir, Daclatasvir, Glecaprevir, Ledipasvir, Pibrentasvir and Velpatasvir showed a binding energy value in range from -8 to -11.2 kcal/mol.	glecaprevir	183-194	ORF1a polyprotein;ORF1ab polyprotein	Severe acute respiratory syndrome coronavirus 2	99-103
31868341-0	2020	Molecular and structural mechanism of pan-genotypic HCV NS3/4A protease inhibition by glecaprevir.	glecaprevir	86-97	KRAS proto-oncogene, GTPase	Homo sapiens	56-59
31868341-2	2020	While older generation direct-acting antivirals (DAAs) had varying effectiveness against different genotypes, the newest NS3/4A protease inhibitors including glecaprevir (GLE) have pan-genotypic activity.	glecaprevir	158-169	KRAS proto-oncogene, GTPase	Homo sapiens	121-124
30903385-0	2019	Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections.	glecaprevir	43-54	genotype 1/2/3	None	125-139
31646465-2	2019	Non-invasive markers, like serum aspartate aminotransferase (AST) to platelet ratio index (APRI), may help identify appropriate HCV treatment-naive patients for 8-week treatment with the pangenotypic regimen of glecaprevir/pibrentasvir.	glecaprevir	211-222	solute carrier family 17 member 5	Homo sapiens	33-59
31646465-2	2019	Non-invasive markers, like serum aspartate aminotransferase (AST) to platelet ratio index (APRI), may help identify appropriate HCV treatment-naive patients for 8-week treatment with the pangenotypic regimen of glecaprevir/pibrentasvir.	glecaprevir	211-222	solute carrier family 17 member 5	Homo sapiens	61-64
32256037-3	2019	CASE REPORT: We describe a case of CHC-MCS treated with the new DAA combination Glecaprevir/Pibrentasvir (GLE/PIB).	glecaprevir	80-91	Miles-Carpenter X-linked mental retardation syndrome	Homo sapiens	39-42
31167814-3	2019	Glecaprevir inhibited P-gp, BCRP, OATP1B1, and OATP1B3 with IC50 values of 0.33, 2.3, 0.017, and 0.064 microM, respectively.	glecaprevir	0-11	ATP binding cassette subfamily B member 1	Homo sapiens	22-26
31167814-3	2019	Glecaprevir inhibited P-gp, BCRP, OATP1B1, and OATP1B3 with IC50 values of 0.33, 2.3, 0.017, and 0.064 microM, respectively.	glecaprevir	0-11	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	28-32
31167814-3	2019	Glecaprevir inhibited P-gp, BCRP, OATP1B1, and OATP1B3 with IC50 values of 0.33, 2.3, 0.017, and 0.064 microM, respectively.	glecaprevir	0-11	solute carrier organic anion transporter family member 1B1	Homo sapiens	34-41
31167814-3	2019	Glecaprevir inhibited P-gp, BCRP, OATP1B1, and OATP1B3 with IC50 values of 0.33, 2.3, 0.017, and 0.064 microM, respectively.	glecaprevir	0-11	solute carrier organic anion transporter family member 1B3	Homo sapiens	47-54
31167814-6	2019	Open-label phase 1 clinical drug-drug interaction studies were conducted in healthy subjects to evaluate interaction potential of glecaprevir/pibrentasvir and coadministered selective substrates for P-gp (digoxin, dabigatran etexilate, and sofosbuvir), BCRP (rosuvastatin and sofosbuvir), and OATP1B1/3 (pravastatin and rosuvastatin).	glecaprevir	130-141	ATP binding cassette subfamily B member 1	Homo sapiens	199-203
31167814-10	2019	The outcomes of the clinical drug-drug interaction studies confirmed clinically relevant inhibition of P-gp, BCRP, and OATP1B1/3, and were used to provide dosing guidance for the concomitant use of glecaprevir/pibrentasvir with relevant transporter substrates.	glecaprevir	198-209	ATP binding cassette subfamily B member 1	Homo sapiens	103-107
31167814-10	2019	The outcomes of the clinical drug-drug interaction studies confirmed clinically relevant inhibition of P-gp, BCRP, and OATP1B1/3, and were used to provide dosing guidance for the concomitant use of glecaprevir/pibrentasvir with relevant transporter substrates.	glecaprevir	198-209	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	109-113
30341499-5	2019	RESULTS: For the approved combination of glecaprevir 300 mg with pibrentasvir 120 mg, glecaprevir AUC was increased by 33% (CP-A), to 2.0-fold (CP-B), and to 11-fold (CP-C) relative to normal subjects; pibrentasvir AUC was <= 26% different (CP-A or CP-B) and increased to 2.1-fold (CP-C).	glecaprevir	41-52	carboxypeptidase A1	Homo sapiens	124-128
30341499-5	2019	RESULTS: For the approved combination of glecaprevir 300 mg with pibrentasvir 120 mg, glecaprevir AUC was increased by 33% (CP-A), to 2.0-fold (CP-B), and to 11-fold (CP-C) relative to normal subjects; pibrentasvir AUC was <= 26% different (CP-A or CP-B) and increased to 2.1-fold (CP-C).	glecaprevir	41-52	carboxypeptidase B1	Homo sapiens	144-148
30341499-5	2019	RESULTS: For the approved combination of glecaprevir 300 mg with pibrentasvir 120 mg, glecaprevir AUC was increased by 33% (CP-A), to 2.0-fold (CP-B), and to 11-fold (CP-C) relative to normal subjects; pibrentasvir AUC was <= 26% different (CP-A or CP-B) and increased to 2.1-fold (CP-C).	glecaprevir	41-52	carboxypeptidase A1	Homo sapiens	244-248
30341499-5	2019	RESULTS: For the approved combination of glecaprevir 300 mg with pibrentasvir 120 mg, glecaprevir AUC was increased by 33% (CP-A), to 2.0-fold (CP-B), and to 11-fold (CP-C) relative to normal subjects; pibrentasvir AUC was <= 26% different (CP-A or CP-B) and increased to 2.1-fold (CP-C).	glecaprevir	41-52	carboxypeptidase B1	Homo sapiens	252-256
30341499-5	2019	RESULTS: For the approved combination of glecaprevir 300 mg with pibrentasvir 120 mg, glecaprevir AUC was increased by 33% (CP-A), to 2.0-fold (CP-B), and to 11-fold (CP-C) relative to normal subjects; pibrentasvir AUC was <= 26% different (CP-A or CP-B) and increased to 2.1-fold (CP-C).	glecaprevir	86-97	carboxypeptidase A1	Homo sapiens	124-128
30341499-5	2019	RESULTS: For the approved combination of glecaprevir 300 mg with pibrentasvir 120 mg, glecaprevir AUC was increased by 33% (CP-A), to 2.0-fold (CP-B), and to 11-fold (CP-C) relative to normal subjects; pibrentasvir AUC was <= 26% different (CP-A or CP-B) and increased to 2.1-fold (CP-C).	glecaprevir	86-97	carboxypeptidase B1	Homo sapiens	144-148
30341499-5	2019	RESULTS: For the approved combination of glecaprevir 300 mg with pibrentasvir 120 mg, glecaprevir AUC was increased by 33% (CP-A), to 2.0-fold (CP-B), and to 11-fold (CP-C) relative to normal subjects; pibrentasvir AUC was <= 26% different (CP-A or CP-B) and increased to 2.1-fold (CP-C).	glecaprevir	86-97	carboxypeptidase A1	Homo sapiens	244-248
30341499-5	2019	RESULTS: For the approved combination of glecaprevir 300 mg with pibrentasvir 120 mg, glecaprevir AUC was increased by 33% (CP-A), to 2.0-fold (CP-B), and to 11-fold (CP-C) relative to normal subjects; pibrentasvir AUC was <= 26% different (CP-A or CP-B) and increased to 2.1-fold (CP-C).	glecaprevir	86-97	carboxypeptidase B1	Homo sapiens	252-256
30341499-6	2019	For glecaprevir 200 mg with pibrentasvir 120 mg, glecaprevir AUC was increased by 80% (CP-A) or to 2.8-fold (CP-B), while pibrentasvir AUC was unaffected in the same subjects (<= 12% difference).	glecaprevir	4-15	carboxypeptidase A1	Homo sapiens	87-91
30341499-6	2019	For glecaprevir 200 mg with pibrentasvir 120 mg, glecaprevir AUC was increased by 80% (CP-A) or to 2.8-fold (CP-B), while pibrentasvir AUC was unaffected in the same subjects (<= 12% difference).	glecaprevir	4-15	carboxypeptidase B1	Homo sapiens	109-113
30341499-6	2019	For glecaprevir 200 mg with pibrentasvir 120 mg, glecaprevir AUC was increased by 80% (CP-A) or to 2.8-fold (CP-B), while pibrentasvir AUC was unaffected in the same subjects (<= 12% difference).	glecaprevir	49-60	carboxypeptidase A1	Homo sapiens	87-91
30341499-6	2019	For glecaprevir 200 mg with pibrentasvir 120 mg, glecaprevir AUC was increased by 80% (CP-A) or to 2.8-fold (CP-B), while pibrentasvir AUC was unaffected in the same subjects (<= 12% difference).	glecaprevir	49-60	carboxypeptidase B1	Homo sapiens	109-113
30341499-11	2019	Elevated glecaprevir and/or pibrentasvir exposures are expected in HCV-infected patients with CP-B or CP-C hepatic impairment.	glecaprevir	9-20	carboxypeptidase B1	Homo sapiens	94-98
31167814-10	2019	The outcomes of the clinical drug-drug interaction studies confirmed clinically relevant inhibition of P-gp, BCRP, and OATP1B1/3, and were used to provide dosing guidance for the concomitant use of glecaprevir/pibrentasvir with relevant transporter substrates.	glecaprevir	198-209	solute carrier organic anion transporter family member 1B1	Homo sapiens	119-126
29084747-1	2018	Glecaprevir (formerly ABT-493) is a novel hepatitis C virus (HCV) NS3/4A protease inhibitor (PI) with pangenotypic activity.	glecaprevir	0-11	KRAS proto-oncogene, GTPase	Homo sapiens	66-69
28688001-8	2018	High glecaprevir exposures at 700 and 1200 mg were associated with grade 2/3 elevations in alanine aminotransferase, aspartate aminotransferase, and/or bilirubin.	glecaprevir	5-16	glutamic--pyruvic transaminase	Homo sapiens	91-115
29180522-1	2018	Glecaprevir and pibrentasvir are hepatitis C virus (HCV) pangenotypic inhibitors targeting NS3/4A protease and NS5A, respectively.	glecaprevir	0-11	KRAS proto-oncogene, GTPase	Homo sapiens	91-94
29180522-10	2018	The glecaprevir-pibrentasvir combination regimen allows a simplified treatment option without the need for HCV subtyping or baseline resistance testing for DAA-naive GT1- or GT2-infected patients.	glecaprevir	4-15	beta-1,4-galactosyltransferase 1	Homo sapiens	166-169
29084747-1	2018	Glecaprevir (formerly ABT-493) is a novel hepatitis C virus (HCV) NS3/4A protease inhibitor (PI) with pangenotypic activity.	glecaprevir	22-29	KRAS proto-oncogene, GTPase	Homo sapiens	66-69
29084747-5	2018	In drug-resistant colony selection studies, glecaprevir generally selected substitutions at NS3 amino acid position A156 in replicons containing proteases from genotypes 1a, 1b, 2a, 2b, 3a, and 4a and substitutions at position D/Q168 in replicons containing proteases from genotypes 3a, 5a, and 6a.	glecaprevir	44-55	KRAS proto-oncogene, GTPase	Homo sapiens	92-95
29084747-6	2018	Although the substitutions A156T and A156V in NS3 of genotype 1 reduced susceptibility to glecaprevir, replicons with these substitutions demonstrated a low replication efficiency in vitro Glecaprevir is active against HCV with most of the common NS3 amino acid substitutions that are associated with reduced susceptibility to other currently approved HCV PIs, including those at positions 155 and 168.	glecaprevir	90-101	KRAS proto-oncogene, GTPase	Homo sapiens	46-49
29084747-6	2018	Although the substitutions A156T and A156V in NS3 of genotype 1 reduced susceptibility to glecaprevir, replicons with these substitutions demonstrated a low replication efficiency in vitro Glecaprevir is active against HCV with most of the common NS3 amino acid substitutions that are associated with reduced susceptibility to other currently approved HCV PIs, including those at positions 155 and 168.	glecaprevir	189-200	KRAS proto-oncogene, GTPase	Homo sapiens	247-250
34986429-5	2022	Molecular dynamics (MD) simulations confirmed the stability of their Mpro complexes, with the MMPBSA binding free energy (DeltaGbind) ranging between -124 kJ/mol (glecaprevir) and -28.2 kJ/mol (velpatasvir).	glecaprevir	163-174	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	69-73
28951228-0	2018	Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.	glecaprevir	12-23	c virus genotype 2, 4, 5, or 6	None	82-112
34986429-8	2022	Glecaprevir and nelfinavir (DeltaGbind = -95.4 kJ/mol) appear to be the most effective antiviral drugs against Mpro.	glecaprevir	0-11	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	111-115
34125405-1	2021	INTRODUCTION: Glecaprevir/pibrentasvir is approved for treating chronic hepatitis C virus (HCV) genotypes (GT) 1-6.	glecaprevir	14-25	beta-1,4-galactosyltransferase 1	Homo sapiens	96-114
35024454-2	2022	Methods: A total of 230 patients from 12 centers in northern Tohoku Japan with chronic hepatitis (CH) or compensated liver cirrhosis (LC) and GT1/2 HCV infection were treated with glecaprevir/pibrentasvir and followed up for 12 weeks after treatment completion.	glecaprevir	180-191	beta-1,4-galactosyltransferase 1	Homo sapiens	142-147
35552472-1	2022	Glecaprevir is a substrate for organic anion-transporting polypeptide (OATP) 1B1/1B3, which transports bilirubin.	glecaprevir	0-11	solute carrier organic anion transporter family member 1B1	Homo sapiens	31-84
34053916-0	2021	Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials.	glecaprevir	23-34	phase ii/iii	None	119-131
34407270-2	2021	This study sought to investigate the effects of glecaprevir/pibrentasvir (G/P), a CYP3A4 substrate and inhibitor, on weight-adjusted tacrolimus (FK) trough/dose ratio (T/D) following heart or kidney transplantation.	glecaprevir	48-59	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	82-88
35024454-11	2022	Conclusion: Primary treatment and re-treatment with glecaprevir/pibrentasvir are effective and safe for patients without decompensated LC and GT1/2 HCV infection in a real-world clinical setting.	glecaprevir	52-63	beta-1,4-galactosyltransferase 1	Homo sapiens	142-147